14504-08-6

Basic information

• Product Name: Benzoic acid, 2-(acetyloxy)-5-methyl-
• CAS NO: 14504-08-6
• Molecular Formula: C10H10O4
• Molecular Weight: 194.187
• Mol File: 14504-08-6.mol
• Article Data: 14

Chemical Properties

• CAS DataBase Reference: Benzoic acid, 2-(acetyloxy)-5-methyl-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzoic acid, 2-(acetyloxy)-5-methyl-(14504-08-6)
• EPA Substance Registry System: Benzoic acid, 2-(acetyloxy)-5-methyl-(14504-08-6)

Safety Data

• Hazardous Substances Data: 14504-08-6(Hazardous Substances Data)

Upstream product

• 89-56-5 5-Methylsalicylic acid 
• 121-44-8 triethylamine 
• 75-36-5 acetyl chloride 
• 108-24-7 acetic anhydride 
• 67-64-1 acetone 
• 67-66-3 chloroform 
• 7726-95-6 bromine 

Downstream Products

• 41773-41-5 6-methyl-3-acetyl-4-hydroxy-2H-benzopyran-2-one 
• 770719-77-2 ethyl [(2-acetoxy-5-methylphenyl)hydroxymethylidene]acetylacetate 
• 770719-71-6 ethyl [(2-acetoxy-5-methylphenyl)hydroxymethylidene]ethoxycarbonylacetate 
• 15083-15-5 C₂₀H₁₈O₇ 
• 1237520-18-1 C₃₆H₄₅N₃O₇ 
• 1237515-64-8 tert-butyl 2-(2-hydroxy-5-methylbenzamido)-4-phenylbenzoate 
• 1237515-89-7 2-(5-(((2-(dimethylamino)ethyl)(methyl)amino)methyl)-2-hydroxybenzamido)-4-phenylbenzoic acid 
• 1237520-19-2 tert-butyl 2-(5-(((2-(dimethylamino)ethyl)(methyl)amino)methyl)-2-(methoxymethoxy)benzamido)-4-phenylbenzoate 
• 1237520-16-9 tert-butyl 2-(2-(methoxymethoxy)-5-((piperidin-1-yl)methyl)benzamido)-4-phenylbenzoate 
• 1237520-14-7 tert-butyl 2-(2-(methoxymethoxy)-5-((4-propylpiperazin-1-yl)methyl)benzamido)-4-phenylbenzoate 

Relevant articles and documents

Development of methylated cobalt–alkyne complexes with selective cytotoxicity against COX-positive cancer cell lines

Derivatives of the cytotoxic cyclooxygenase (COX) inhibitor [(prop-2-ynyl)?2-acetoxybenzoate]dicobalthexacarbonyl (Co-ASS) with a methyl group in the 3, 4, 5, or 6 position of the acetylsalicylic acid (ASS) scaffold were synthesized with the aim to achieve enhanced selectivity for COX-2. From this modification, a higher specificity for COX-2-expressing tumors is expected, preventing COX-1-mediated side effects. The cobalt–alkyne complexes were tested for their COX-inhibitory and antiproliferative properties as well as their cellular uptake. Methylation reduced the effects at the isolated COX-1, whereas those at the isolated COX-2 remained nearly constant compared to Co-ASS. In cellular systems, the new compounds showed superior cytotoxicity toward the COX-positive HT-29 colon carcinoma cells than cisplatin. The reduced growth-inhibitory potency in T-24 cells, which express distinctly fewer COX enzymes (COX-1/COX-2 = 50/1) than HT-29 cells (COX-1/COX-2 = 50/50), and the only marginal activity in COX-negative MCF-7 breast cancer cells point to an interference in the arachidonic acid cascade through COX-2 inhibition as part of the mode of action, especially as the cellular uptake was even higher in MCF-7 cells than in T-24 cells. These findings clearly demonstrate that the methylated cobalt–alkyne complexes possess promising potential for further development as reasonable alternatives to the limited platinum-based antitumor agents.

Small-molecules that covalently react with a human prolyl hydroxylase-towards activity modulation and substrate capture

We describe covalently binding modulators of the activity of human prolyl hydroxylase domain 2 (PHD2) and studies towards a strategy for photocapture of PHD2 substrates. Reversible active site binding of electrophile bearing compounds enables susbsequent covalent reaction with a lysine residue (K408) in the flexible C-terminal region of PHD2 to give a modified protein that retains catalytic activity.

COMPOUNDS USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES

The present invention refers to compounds of formula: (formula A), wherein R1 is selected from (formula I), (formula II), (formula (III), (formula IV), (formula V), or (formula B), and wherein R2, R3, R4 and Rs